Scribe Therapeutics raised $128.7 million gross in its IPO for in vivo gene editing and pushed the offering to the top of its range. The company’s lead program, STX-1150, is designed to silence PCSK9 to lower LDL cholesterol, with an ongoing Phase 1 study launched in Australia. Scribe said it plans additional clinical spending across other preclinical lipid programs, including STX-1400 (APOC3) and STX-1200 (LPA), as it seeks to broaden its lipid-lowering pipeline beyond rare-disease entrants in the PCSK9 space. The company’s valuation and capital plan are aimed at moving from early clinical evidence toward IND-enabling expansion and later trial readiness. The IPO also underscores continuing investor appetite for gene-silencing platforms that can deliver single-treatment durability while competing with established genetic modalities entering regulatory review.